We are live on ! Find out more
TRV

Third Rock Ventures Portfolio holdings

AUM $1.07B
1-Year Est. Return 170.23%
This Fund
S&P 500
This Quarter Est. Return
+13.05%
1 Year Est. Return
+170.23%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$468M
AUM Growth
-$95.7M
Cap. Flow
-$110M
Cap. Flow %
-23.42%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
2
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$68M
2
FMI
Foundation Medicine, Inc.
FMI
+$41.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
1
Agios Pharmaceuticals
AGIO
$2.38B
$178M 38.11%
3,895,090
-1,669,324
-30% -$68M
FMI
2
DELISTED
Foundation Medicine, Inc.
FMI
$133M 28.36%
4,927,234
-1,642,411
-25% -$41.6M
BLUE
3
DELISTED
bluebird bio
BLUE
$93.2M 19.9%
186,590
– –
CARM
4
DELISTED
Carisma Therapeutics
CARM
$63.8M 13.63%
242,080
– –

Similar funds

AH
Achievement Holdings Chicago, Illinois $1.2B AUM 9.2% 1-Year Est. Return
GHF
Good Harbor Financial Barrington, Illinois $916M AUM 5.96% 1-Year Est. Return
CWA
Constellation Wealth Advisors New York $903M AUM 2.38% 1-Year Est. Return
RI
Relational Investors San Diego, California $840M AUM 0.57% 1-Year Est. Return
TCM
Tamarack Capital Management Carlsbad, California $840M AUM 19.47% 1-Year Est. Return
F
FutureAdvisor San Francisco, California $617M AUM 6.57% 1-Year Est. Return
MCC
Mid Continent Capital Chicago, Illinois $1.54B AUM 0.7% 1-Year Est. Return
OA
OFI Advisors Philadelphia, Pennsylvania $1.55B AUM 1.44% 1-Year Est. Return

Third Rock Ventures's Q2 2014 Portfolio in Review

As of Q2 2014, Third Rock Ventures held 4 positions worth $468M, down 17% from $564M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Third Rock Ventures withdrew a net $110M in Q2 2014, reducing 2 holdings. Its largest reduction was Agios Pharmaceuticals, cutting an estimated $68M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Third Rock Ventures's biggest Q2 2014 reduction was Agios Pharmaceuticals, cutting an estimated $68M.
  • Third Rock Ventures's ten largest holdings make up 100% of its $468M portfolio in Q2 2014.
  • Third Rock Ventures opened 0 new positions and closed 0 in Q2 2014.
  • Third Rock Ventures's portfolio value fell 17% quarter-over-quarter to $468M.

Based on Third Rock Ventures's 13F filing for Q2 2014, filed 30 Jul 2014.